Array Technologies initiated with an Overweight at Wells Fargo 06:47 ARRY Wells Fargo analyst Michael Blum initiated coverage of Array Technologies with an Overweight rating and $28 price target. The analyst projects Array to grow revenues at a CAGR of 10%, driven by policy support, Solar's low cost, and state/federal utility mandates to de-carbonize and achieve net zero targets. While Blum expects near-term growth could be muted due to restrictive government policies on solar panel imports, he likes the long-term prospects for utility-scale solar and sees Array at an inflection point to higher margins and free cash flow generation. Xponential Fitness initiated with a Buy at Citi
My favorite $1 stock? Glad you asked- This is one of them- Energous gets approval for 1W WattUp PowerBridge technology in South Korea 06:13 WATT Energous announced that its 1W WattUp PowerBridge transmitter technology has been approved in South Korea for unlimited wireless power distance transmission for IoT applications. Energous' WattUp PowerBridge supports wireless power transfer for multiple next-generation applications including smart tags, electronic shelf labels, sensors, asset trackers and more.
This could be interesting. Emergent BioSolutions: FDA accepts for review sNDA for Narcan Nasal Spray » 06:11 EBS On the one hand a guy out cold in the street he can't inhale so you need the jab-- But for your average junkie at home... having one of these sprays available might be very wise... just before you know out you take a big Narcan hit. This could save lives.
HIGHER AFTER EARNINGS GitLab (GTLB) up 20.4%<--------------- Powell Industries (POWL) up 18.2% Evolus (EOLS) up 11.9% Sumo Logic (SUMO) up 11.7%
I am a seasoned bio investor obviously. When I have trouble understanding a PR it can be bad-- Mirati Therapeutics announces results from KRYSTAL-7, KRYSTAL-1 trials 18:08 MRTX Mirati Therapeutics announced preliminary results from the KRYSTAL-7 Phase 2 trial and KRYSTAL-1 Phase 1b cohort evaluating adagrasib concurrently combined with pembrolizumab in patients for the treatment of first-line NSCLC harboring a KRASG12C mutation across all PD-L1 subgroups. These data are the first to demonstrate the tolerability and feasibility of a concurrent combination regimen of a KRASG12C inhibitor and a PD-1/L1 checkpoint inhibitor. The KRYSTAL-7 and KRYSTAL-1 trials represent the largest dataset evaluating a KRASG12C inhibitor in combination with a PD-1/L1 checkpoint inhibitor as a first-line treatment for patients with NSCLC harboring a KRASG12C mutation. 75 patients were enrolled and evaluable for safety with a median follow-up of 3.5 months. Treatment-related adverse events were Grade 1-2 (39%), Grade 3 (40%) and Grade 4 (4%); there were no Grade 5 TRAEs observed. TRAEs led to discontinuation of both adagrasib and pembrolizumab in 2 patients and only pembrolizumab in 2 patients; there were no patients who discontinued only adagrasib due to a TRAE. Increases in alanine transaminase/ aspartate transaminase were consistent with either agent as a monotherapy with Grade 3 TRAEs being highest grade and total incidence of Grade 3 liver function test increases of 9%. Median time from onset to an increase in ALT and AST was 26 and 37 days, respectively and only 1 patient experienced new onset treatment-related ALT/AST increase after 3 months. Of patients who were clinically evaluable and received at least one on-study scan, adagrasib and pembrolizumab demonstrated promising preliminary clinical activity across all PD-L1 subgroups with an objective response rate of 49%. In a subset of response-evaluable patients enrolled at least 6 months prior to the data cutoff date, 6 of 26 clinical responses occurred at second on-study scan or later, and the ORR was 56%. 7 evaluable patients enrolled in the KRYSTAL-1 Phase 1b cohort reported an ORR of 57% and a disease control rate of 100%....
Man I'm nervous. I just Averaged UP here as well and it should of been up in the Pre-- and I don't see it.. GBA' Christmas 6 pack includes this name. Ugh.
I bet we have a secrete battle plan for Taiwan that goes something like this... 100 helicopters arrive at rooftop of Taiwan Semi all employees are evacuated to aircraft carrier. 2nd team removes all electronics and tech and loads into 10 C-130's. Planes and aircraft carrier head to Arizona. The People of Taiwan are wished " good luck " Taiwan Semiconductor lifts chip investment in Arizona to $40B
Today's Gummy- Wait for re trace. EBS Emergent BioSolutions Inc. $11.79-0.21(-1.75%)11:00 AM 12/05/22 NYSE |$USD |Pre-Market:$12.94+1.15->(+9.75%)